260 related articles for article (PubMed ID: 22742565)
1. Germline prognostic markers for urinary bladder cancer: obstacles and opportunities.
Chang DW; Gu J; Wu X
Urol Oncol; 2012; 30(4):524-32. PubMed ID: 22742565
[TBL] [Abstract][Full Text] [Related]
2. Prognostic markers for urothelial cancer: obstacles and opportunities.
Malmström PU
Urol Oncol; 2012; 30(4):516-7. PubMed ID: 22742563
[No Abstract] [Full Text] [Related]
3. The bladder cancer genome; chromosomal changes as prognostic makers, opportunities, and obstacles.
Höglund M
Urol Oncol; 2012; 30(4):533-40. PubMed ID: 22742566
[TBL] [Abstract][Full Text] [Related]
4. Can we use methylation markers as diagnostic and prognostic indicators for bladder cancer?
Kim YJ; Kim WJ
Investig Clin Urol; 2016 Jun; 57 Suppl 1(Suppl 1):S77-88. PubMed ID: 27326410
[TBL] [Abstract][Full Text] [Related]
5. Germline genetic markers for urinary bladder cancer risk, prognosis and treatment response.
Grotenhuis AJ; Vermeulen SH; Kiemeney LA
Future Oncol; 2010 Sep; 6(9):1433-60. PubMed ID: 20919828
[TBL] [Abstract][Full Text] [Related]
6. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
[TBL] [Abstract][Full Text] [Related]
7. Genetic and epigenetic aspects of bladder cancer.
Kim WJ; Quan C
J Cell Biochem; 2005 May; 95(1):24-33. PubMed ID: 15759278
[TBL] [Abstract][Full Text] [Related]
8. Urinary bladder cancer susceptibility markers. What do we know about functional mechanisms?
Dudek AM; Grotenhuis AJ; Vermeulen SH; Kiemeney LA; Verhaegh GW
Int J Mol Sci; 2013 Jun; 14(6):12346-66. PubMed ID: 23752272
[TBL] [Abstract][Full Text] [Related]
9. Identification of biomarkers associated with progression and prognosis in bladder cancer via co-expression analysis.
Shi S; Tian B
Cancer Biomark; 2019; 24(2):183-193. PubMed ID: 30689556
[TBL] [Abstract][Full Text] [Related]
10. Cumulative effect of genome-wide association study-identified genetic variants for bladder cancer.
Wang M; Chu H; Lv Q; Wang L; Yuan L; Fu G; Tong N; Qin C; Yin C; Zhang Z; Xu J
Int J Cancer; 2014 Dec; 135(11):2653-60. PubMed ID: 24740636
[TBL] [Abstract][Full Text] [Related]
11. A Three Protein-Coding Gene Prognostic Model Predicts Overall Survival in Bladder Cancer Patients.
Ning XH; Qi YY; Wang FX; Li SC; Jia ZK; Yang JJ
Biomed Res Int; 2020; 2020():7272960. PubMed ID: 33150179
[TBL] [Abstract][Full Text] [Related]
12. The Bladder EpiCheck Test as a Non-Invasive Tool Based on the Identification of DNA Methylation in Bladder Cancer Cells in the Urine: A Review of Published Evidence.
Mancini M; Righetto M; Zumerle S; Montopoli M; Zattoni F
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32911596
[TBL] [Abstract][Full Text] [Related]
13. Molecular aspects of bladder cancer III. Prognostic markers of bladder cancer.
Kausch I; Böhle A
Eur Urol; 2002 Jan; 41(1):15-29. PubMed ID: 11999461
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic biomarkers in urothelial bladder cancer.
Kim WJ; Kim YJ
Expert Rev Mol Diagn; 2009 Apr; 9(3):259-69. PubMed ID: 19379084
[TBL] [Abstract][Full Text] [Related]
15. Combining molecular and pathologic data to prognosticate non-muscle-invasive bladder cancer.
van Rhijn BW
Urol Oncol; 2012; 30(4):518-23. PubMed ID: 22742564
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic value of fibronectin and mutant p53 in the urine of patients with bladder cancer: impact on clinicopathological features and disease recurrence.
Eissa S; Zohny SF; Zekri AR; El-Zayat TM; Maher AM
Med Oncol; 2010 Dec; 27(4):1286-94. PubMed ID: 20012564
[TBL] [Abstract][Full Text] [Related]
17. Molecular biomarkers in urothelial bladder cancer.
Kim WJ; Bae SC
Cancer Sci; 2008 Apr; 99(4):646-52. PubMed ID: 18377416
[TBL] [Abstract][Full Text] [Related]
18. Functional polymorphisms in the matrix metalloproteinase genes and their association with bladder cancer risk and recurrence: a mini-review.
Wieczorek E; Wasowicz W; Gromadzinska J; Reszka E
Int J Urol; 2014 Aug; 21(8):744-52. PubMed ID: 24635493
[TBL] [Abstract][Full Text] [Related]
19. Molecular Biomarkers of Bladder Cancer: A Mini-Review.
Varchulová Nováková Z; Kuniaková M; Žiaran S; Harsányi Š
Physiol Res; 2023 Oct; 72(S3):S247-S256. PubMed ID: 37888968
[TBL] [Abstract][Full Text] [Related]
20. [Characterisation of DNA methylation biomarkers for bladder cancer].
Antony P; Rose M; Gaisa NT; Alkaya S; Heidenreich A; Knüchel R; Dahl E
Pathologe; 2010 Oct; 31 Suppl 2():244-50. PubMed ID: 20798943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
